Related Experiment Video
Updated: Jan 20, 2026
Producing Monoclonal Antibodies Using Hybridomas
Published on: April 30, 2023
Current Development of Monoclonal Antibodies in Cancer Therapy
Sagun Parakh1,2,3, Dylan King1,3, Hui K Gan1,2,3
1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, VIC, 3084, Australia.
Abstract:
Exploiting the unique specificity of monoclonal antibodies has revolutionized the treatment and diagnosis of haematological and solid organ malignancies; bringing benefit to millions of patients over the past decades. Recent achievements include conjugating antibodies with toxic payloads resulting in superior efficacy and/or reduced toxicity, development of molecular imaging techniques targeting specific antigens for use as predictive and prognostic biomarkers, the development of novel bi- and tri-specific antibodies to enhance therapeutic benefit and abrogate resistance and the success of immunotherapy agents. In this chapter, we review an overview of antibody structure and function relevant to cancer therapy and provide an overview of pivotal clinical trials which have led to regulatory approval of monoclonal antibodies in cancer treatment. We further discuss resistance mechanisms and the unique side effects of each class of antibody and provide an overview of emerging therapeutic agents.
Insights
Monoclonal antibodies have transformed cancer care, offering new diagnostic and treatment options for various malignancies. This review covers their structure, function, clinical trials, and emerging therapeutic strategies in oncology.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Monoclonal antibodies (mAbs) have revolutionized cancer diagnosis and treatment, benefiting millions.
- Recent advancements include antibody-drug conjugates, molecular imaging, bispecific antibodies, and immunotherapies.
Purpose of the Study:
- To provide an overview of antibody structure and function in cancer therapy.
- To review pivotal clinical trials leading to regulatory approval of mAbs in cancer treatment.
- To discuss resistance mechanisms, side effects, and emerging therapeutic agents.
Main Methods:
- Literature review of antibody structure, function, and clinical applications in oncology.
- Analysis of key clinical trials and regulatory approvals for monoclonal antibodies.
- Discussion of resistance mechanisms, adverse effects, and novel antibody-based therapies.
Main Results:
- Monoclonal antibodies have demonstrated significant efficacy in treating hematological and solid organ malignancies.
- Various strategies, including antibody-drug conjugates and bispecific antibodies, enhance therapeutic outcomes.
- Emerging antibody-based agents show promise for future cancer treatment.
Conclusions:
- Monoclonal antibodies represent a cornerstone of modern cancer therapy, with ongoing innovation expanding their clinical utility.
- Understanding antibody mechanisms, resistance, and side effects is crucial for optimizing patient care.
- Future directions involve novel antibody formats and combination therapies to overcome treatment challenges.
Related Concept Videos
13:21Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455
2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455
3 Department of Urology, University of Minnesota, Minneapolis, MN 55455
4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455
Polyclonal antibodies are defined as a collection of antibodies directed against...
12:15Generation of Monoclonal Antibodies Against Natural Products
09:42Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:57Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
04:51A Hybridoma Technology for Producing Monoclonal Antibodies against a Metallopeptidase
03:03An Affinity Chromatography Technique for the Purification of Monoclonal Antibodies